 Joseph Rosenthal
Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Marrow Transplantation | 7 | 2024 | 286 | 0.910 |
Why?
| | Brain Injuries, Traumatic | 4 | 2016 | 360 | 0.880 |
Why?
| | Antibodies, Bacterial | 3 | 2016 | 146 | 0.670 |
Why?
| | Brain Ischemia | 4 | 2022 | 338 | 0.570 |
Why?
| | Bacterial Vaccines | 2 | 2016 | 63 | 0.570 |
Why?
| | Bacterial Outer Membrane Proteins | 2 | 2016 | 58 | 0.560 |
Why?
| | Antigens, Bacterial | 2 | 2016 | 127 | 0.550 |
Why?
| | Fatigue | 2 | 2016 | 329 | 0.540 |
Why?
| | Neurological Rehabilitation | 1 | 2016 | 9 | 0.520 |
Why?
| | Graft vs Host Disease | 4 | 2022 | 252 | 0.450 |
Why?
| | Models, Neurological | 1 | 2016 | 242 | 0.440 |
Why?
| | Vaccines, Virus-Like Particle | 1 | 2013 | 3 | 0.430 |
Why?
| | Th1 Cells | 1 | 2014 | 143 | 0.430 |
Why?
| | Stroke | 4 | 2022 | 1120 | 0.400 |
Why?
| | Seizures | 1 | 2016 | 426 | 0.390 |
Why?
| | Drug Carriers | 1 | 2013 | 128 | 0.390 |
Why?
| | Escherichia coli | 3 | 2016 | 815 | 0.380 |
Why?
| | Blindness, Cortical | 1 | 2011 | 5 | 0.350 |
Why?
| | Sports | 1 | 2014 | 231 | 0.350 |
Why?
| | Autonomic Dysreflexia | 1 | 2011 | 4 | 0.350 |
Why?
| | Quadriplegia | 1 | 2011 | 12 | 0.350 |
Why?
| | Population Surveillance | 1 | 2014 | 482 | 0.340 |
Why?
| | Athletes | 1 | 2014 | 423 | 0.330 |
Why?
| | Students | 1 | 2014 | 622 | 0.290 |
Why?
| | Vaccines | 1 | 2013 | 406 | 0.290 |
Why?
| | Nanoparticles | 1 | 2013 | 481 | 0.280 |
Why?
| | Endovascular Procedures | 2 | 2022 | 312 | 0.270 |
Why?
| | Athletic Injuries | 1 | 2014 | 529 | 0.270 |
Why?
| | Hospitalization | 1 | 2016 | 2199 | 0.250 |
Why?
| | Lymphoma | 2 | 2024 | 208 | 0.230 |
Why?
| | Transplantation, Homologous | 3 | 2022 | 416 | 0.220 |
Why?
| | Maximum Tolerated Dose | 1 | 2024 | 199 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2024 | 65 | 0.210 |
Why?
| | Vaccines, Synthetic | 2 | 2014 | 126 | 0.210 |
Why?
| | Accidental Falls | 2 | 2016 | 196 | 0.210 |
Why?
| | Azacitidine | 1 | 2024 | 140 | 0.200 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2022 | 24 | 0.200 |
Why?
| | Myelodysplastic Syndromes | 1 | 2024 | 135 | 0.190 |
Why?
| | Mechanical Thrombolysis | 1 | 2022 | 4 | 0.190 |
Why?
| | Cell Membrane | 3 | 2014 | 738 | 0.190 |
Why?
| | Arterial Occlusive Diseases | 1 | 2022 | 83 | 0.180 |
Why?
| | Young Adult | 10 | 2024 | 13209 | 0.180 |
Why?
| | Thrombectomy | 4 | 2022 | 69 | 0.180 |
Why?
| | Neurologists | 1 | 2021 | 21 | 0.170 |
Why?
| | Restraint, Physical | 1 | 2021 | 72 | 0.170 |
Why?
| | Law Enforcement | 1 | 2021 | 39 | 0.170 |
Why?
| | Motor Cortex | 1 | 2020 | 61 | 0.170 |
Why?
| | Adult | 15 | 2024 | 37929 | 0.170 |
Why?
| | Brain Injuries | 2 | 2015 | 494 | 0.160 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2020 | 89 | 0.160 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2024 | 630 | 0.160 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2022 | 622 | 0.160 |
Why?
| | Carotid Arteries | 1 | 2021 | 206 | 0.160 |
Why?
| | Gene Expression | 2 | 2014 | 1502 | 0.150 |
Why?
| | Physician's Role | 1 | 2021 | 211 | 0.150 |
Why?
| | Female | 21 | 2024 | 73304 | 0.150 |
Why?
| | Unrelated Donors | 1 | 2019 | 39 | 0.150 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 243 | 0.150 |
Why?
| | Male | 18 | 2024 | 67762 | 0.150 |
Why?
| | Anemia, Aplastic | 1 | 2018 | 38 | 0.150 |
Why?
| | Adolescent | 10 | 2024 | 21513 | 0.140 |
Why?
| | Mice, Inbred BALB C | 3 | 2016 | 1272 | 0.140 |
Why?
| | Alanine | 2 | 2016 | 152 | 0.140 |
Why?
| | Humans | 28 | 2024 | 137585 | 0.140 |
Why?
| | Epilepsy, Post-Traumatic | 1 | 2016 | 3 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 3 | 2022 | 3566 | 0.130 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2016 | 20 | 0.130 |
Why?
| | Neisseria meningitidis, Serogroup B | 1 | 2016 | 16 | 0.130 |
Why?
| | Immunoglobulin Class Switching | 1 | 2016 | 20 | 0.130 |
Why?
| | Sensation Disorders | 1 | 2016 | 37 | 0.130 |
Why?
| | Transport Vesicles | 1 | 2016 | 20 | 0.130 |
Why?
| | Bone Marrow | 3 | 2024 | 286 | 0.130 |
Why?
| | Threonine | 1 | 2016 | 47 | 0.120 |
Why?
| | Polysaccharides | 1 | 2016 | 79 | 0.120 |
Why?
| | Blood Transfusion | 1 | 2018 | 325 | 0.120 |
Why?
| | Tularemia | 1 | 2016 | 29 | 0.120 |
Why?
| | Francisella tularensis | 1 | 2016 | 32 | 0.120 |
Why?
| | Craniotomy | 1 | 2016 | 77 | 0.120 |
Why?
| | Leukemia | 1 | 2018 | 240 | 0.120 |
Why?
| | Immunization | 2 | 2016 | 411 | 0.120 |
Why?
| | Remission Induction | 1 | 2016 | 288 | 0.120 |
Why?
| | Valine | 1 | 2016 | 82 | 0.120 |
Why?
| | International Classification of Diseases | 1 | 2016 | 135 | 0.120 |
Why?
| | Community Participation | 1 | 2016 | 131 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1692 | 0.120 |
Why?
| | Anemia, Sickle Cell | 1 | 2019 | 270 | 0.120 |
Why?
| | Recombinant Fusion Proteins | 2 | 2014 | 665 | 0.120 |
Why?
| | Psychomotor Agitation | 1 | 2015 | 71 | 0.110 |
Why?
| | Geriatric Assessment | 1 | 2016 | 224 | 0.110 |
Why?
| | Hemolysin Proteins | 1 | 2014 | 34 | 0.110 |
Why?
| | Vaccines, Subunit | 1 | 2014 | 49 | 0.110 |
Why?
| | Inpatients | 2 | 2015 | 500 | 0.110 |
Why?
| | Genes, Synthetic | 1 | 1994 | 15 | 0.110 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2844 | 0.110 |
Why?
| | Bungarotoxins | 1 | 1994 | 46 | 0.110 |
Why?
| | Probiotics | 1 | 2014 | 54 | 0.110 |
Why?
| | Triage | 1 | 2016 | 222 | 0.110 |
Why?
| | Time Factors | 4 | 2019 | 6828 | 0.110 |
Why?
| | Epitopes | 1 | 2016 | 479 | 0.110 |
Why?
| | Epidemiologic Studies | 1 | 2014 | 72 | 0.110 |
Why?
| | Aged | 8 | 2024 | 23961 | 0.110 |
Why?
| | Craniocerebral Trauma | 1 | 2016 | 170 | 0.110 |
Why?
| | Postural Balance | 1 | 2016 | 215 | 0.110 |
Why?
| | Long-Term Potentiation | 1 | 2016 | 198 | 0.110 |
Why?
| | Immunity, Humoral | 1 | 2014 | 116 | 0.110 |
Why?
| | Middle Aged | 7 | 2024 | 33479 | 0.100 |
Why?
| | Biomimetics | 1 | 2013 | 44 | 0.100 |
Why?
| | Amyloid beta-Peptides | 1 | 2016 | 220 | 0.100 |
Why?
| | Species Specificity | 1 | 2014 | 585 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5131 | 0.100 |
Why?
| | Sleep Wake Disorders | 1 | 2016 | 286 | 0.100 |
Why?
| | Immunity, Cellular | 1 | 2014 | 268 | 0.100 |
Why?
| | Escherichia coli Proteins | 1 | 2014 | 200 | 0.100 |
Why?
| | Treatment Outcome | 6 | 2024 | 10811 | 0.100 |
Why?
| | Adjuvants, Immunologic | 1 | 2013 | 226 | 0.100 |
Why?
| | Risk Factors | 5 | 2018 | 10388 | 0.090 |
Why?
| | Peptide Fragments | 1 | 2016 | 706 | 0.090 |
Why?
| | Aged, 80 and over | 5 | 2024 | 7635 | 0.090 |
Why?
| | Logistic Models | 1 | 2016 | 2074 | 0.090 |
Why?
| | Thrombolytic Therapy | 2 | 2022 | 142 | 0.090 |
Why?
| | Schools | 1 | 2014 | 461 | 0.080 |
Why?
| | Transplantation, Autologous | 2 | 2024 | 238 | 0.080 |
Why?
| | Depression | 2 | 2016 | 1397 | 0.080 |
Why?
| | Biocompatible Materials | 1 | 2013 | 425 | 0.080 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 240 | 0.070 |
Why?
| | Prospective Studies | 5 | 2021 | 7604 | 0.070 |
Why?
| | Infant | 5 | 2022 | 9465 | 0.070 |
Why?
| | Anxiety | 1 | 2015 | 1035 | 0.070 |
Why?
| | Radiography | 1 | 2011 | 822 | 0.070 |
Why?
| | Emergency Service, Hospital | 2 | 2016 | 2069 | 0.070 |
Why?
| | Child, Preschool | 5 | 2022 | 11074 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 4030 | 0.070 |
Why?
| | Canada | 2 | 2021 | 418 | 0.070 |
Why?
| | Bacteria | 1 | 2014 | 858 | 0.070 |
Why?
| | Incidence | 3 | 2018 | 2804 | 0.060 |
Why?
| | United States | 4 | 2021 | 14841 | 0.060 |
Why?
| | Brain Concussion | 1 | 2014 | 574 | 0.060 |
Why?
| | Child | 6 | 2024 | 21935 | 0.060 |
Why?
| | Mice | 4 | 2016 | 17787 | 0.060 |
Why?
| | Rehabilitation Centers | 2 | 2015 | 39 | 0.060 |
Why?
| | Carbolines | 1 | 2024 | 32 | 0.060 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 20 | 0.060 |
Why?
| | Animals | 6 | 2016 | 36940 | 0.060 |
Why?
| | Survival Rate | 2 | 2019 | 1972 | 0.050 |
Why?
| | Protein Folding | 2 | 2016 | 280 | 0.050 |
Why?
| | Morbidity | 1 | 2024 | 324 | 0.050 |
Why?
| | Infant, Newborn | 3 | 2018 | 6079 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2022 | 15657 | 0.050 |
Why?
| | Age Factors | 2 | 2021 | 3295 | 0.050 |
Why?
| | Reperfusion | 1 | 2021 | 40 | 0.050 |
Why?
| | Cerebral Hemorrhage | 1 | 2021 | 108 | 0.040 |
Why?
| | Neck | 1 | 2021 | 101 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 224 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2022 | 270 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2019 | 126 | 0.040 |
Why?
| | Brain | 1 | 2011 | 2668 | 0.040 |
Why?
| | Transfusion Reaction | 1 | 2018 | 45 | 0.040 |
Why?
| | Allografts | 1 | 2019 | 146 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1079 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 686 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5742 | 0.030 |
Why?
| | Age of Onset | 1 | 2018 | 518 | 0.030 |
Why?
| | Neuroblastoma | 1 | 2018 | 160 | 0.030 |
Why?
| | O Antigens | 1 | 2016 | 9 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2018 | 156 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 2016 | 55 | 0.030 |
Why?
| | Microtomy | 1 | 2016 | 5 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 362 | 0.030 |
Why?
| | Glycosylation | 1 | 2016 | 151 | 0.030 |
Why?
| | Acute Disease | 1 | 2019 | 1007 | 0.030 |
Why?
| | Cause of Death | 1 | 2018 | 434 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 889 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 431 | 0.030 |
Why?
| | Trauma Severity Indices | 1 | 2015 | 106 | 0.030 |
Why?
| | Microscopy, Atomic Force | 1 | 2016 | 126 | 0.030 |
Why?
| | Protein Stability | 1 | 2016 | 176 | 0.030 |
Why?
| | Protein Aggregates | 1 | 2016 | 72 | 0.030 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2016 | 187 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 307 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2016 | 192 | 0.030 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 289 | 0.030 |
Why?
| | Survivors | 1 | 2018 | 493 | 0.030 |
Why?
| | Chromatography, DEAE-Cellulose | 1 | 1994 | 13 | 0.030 |
Why?
| | Electric Organ | 1 | 1994 | 8 | 0.030 |
Why?
| | Torpedo | 1 | 1994 | 10 | 0.030 |
Why?
| | Snakes | 1 | 1994 | 21 | 0.030 |
Why?
| | Factor Xa | 1 | 1994 | 32 | 0.030 |
Why?
| | Bioengineering | 1 | 2014 | 18 | 0.030 |
Why?
| | Aspartic Acid | 1 | 1994 | 79 | 0.030 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1994 | 143 | 0.030 |
Why?
| | Trauma Centers | 1 | 2016 | 421 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2015 | 522 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1994 | 375 | 0.030 |
Why?
| | Point Mutation | 1 | 1994 | 235 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1994 | 534 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 1994 | 374 | 0.030 |
Why?
| | Linear Models | 1 | 2015 | 849 | 0.020 |
Why?
| | Biological Transport | 1 | 2014 | 418 | 0.020 |
Why?
| | Kinetics | 1 | 2016 | 1670 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2071 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1710 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1994 | 1353 | 0.020 |
Why?
| | Hippocampus | 1 | 2016 | 895 | 0.020 |
Why?
| | Cognitive Dysfunction | 1 | 2015 | 383 | 0.020 |
Why?
| | Base Sequence | 1 | 1994 | 2181 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2014 | 443 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 1994 | 2139 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 2224 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1994 | 2900 | 0.020 |
Why?
| | Models, Molecular | 1 | 1994 | 1570 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2734 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1587 | 0.020 |
Why?
| | Vaccination | 1 | 2016 | 1381 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3457 | 0.020 |
Why?
| | Mutation | 1 | 2016 | 3958 | 0.010 |
Why?
|
|
Rosenthal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|